insulin lispro (Wockhardt)

Insulin lispro (Wockhardt) is a biosimilar version of the rapid-acting insulin analogue, insulin lispro, which was originally developed and marketed by Eli Lilly as Humalog. Developed by the Indian pharmaceutical company Wockhardt Ltd, this recombinant protein biologic is designed for subcutaneous administration to manage postprandial blood glucose levels in patients with type 1 diabetes mellitus. The drug functions by binding to and activating the insulin receptor, which stimulates glucose uptake into peripheral tissues such as skeletal muscle and fat, while simultaneously inhibiting hepatic glucose production. Wockhardt intended to market the product under the brand name Listro, including various premixed formulations. However, the clinical development program in the United States was largely discontinued following the withdrawal of a Phase 3 trial and multiple Phase 1 studies in early 2013.

Brand names

ListroListro Mix 50/50Listro Mix 75/25

Other names

Wockhardt's insulin lisproWockhardt's recombinant insulin analogueListroMix 50/50